Study-context terms explain dose, route, formulation, timing, and endpoint.
Dictionary / Study context
Dose
Amount, timing, frequency, and formulation context behind a source-backed row.
Study contextterm category
0related public pages
editorial navigationdefinition status
draftreview status
40exact evidence rows
23exact source links
0nearby evidence rows
0nearby source links
0do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Dose explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
23 direct sources linked to approved workbench claims. PubMed 37796540
0 nearby evidence rows and 0 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Dose is used in this encyclopedia as a study context term. Amount, timing, frequency, and formulation context behind a source-backed row.
Study-context terms explain the conditions around a source: route, dose, formulation, timing, population, model, duration, and endpoint.
No common aliases are listed for this term yet.
Evidence Guardrail
How to read it without overreaching
Study context is the difference between a useful evidence row and an overread claim. Keep this term attached to the exact source, product, model, timing, and endpoint wherever possible.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 37796540
Distinct source records under those exact rows. PubMed 37796540
Source-backed public pages where this vocabulary is likely useful.
Evidence rows available on those related public pages.
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 37796540
- Open related pages.Use nearby pages for broader source-backed context.
- Keep the boundary.Study context changes what a source can support, so keep it attached to the row.
Exact Evidence Rows
Approved source-backed rows linked to this term
40 exact rows
No matching evidence rows.
Evidence Group
Preliminary Human
23 exact rows / 11 sources
Evidence row 2 / uses term
CBN decreases Nighttime awakenings.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 3 / uses term
CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 4 / uses term
CBN decreases Overall sleep disturbance.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 5 / uses term
CBN no detected effect on Side effect frequency.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 6 / uses term
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 7 / uses term
CBN decreases Sleep onset latency.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 8 / uses term
CBN increases Subjective sleep quality.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 9 / uses term
CBN increases NREM-2 sleep.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 14 / uses term
CBN decreases Overall sleep disturbance.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 15 / uses term
CBN associated with Adverse events.
preliminary human / low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 16 / uses term
CBN no detected effect on Sleep onset latency.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 17 / uses term
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 18 / uses term
CBN no detected effect on Daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 57 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PubMed 38174873
Claim or source metadata contains an explicit term marker.
Evidence row 120 / uses term
CBDV studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. PubMed 34210360
Claim or source metadata contains an explicit term marker.
Evidence row 122 / uses term
CBDV studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. PubMed 31748505
Claim or source metadata contains an explicit term marker.
Evidence row 159 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 396 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. PubMed 42256679
Claim or source metadata contains an explicit term marker.
Evidence row 403 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PubMed 38174873
Claim or source metadata contains an explicit term marker.
Evidence row 469 / uses term
THC studied for Cognition and memory.
preliminary human / very_low confidence.
Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. PubMed 12373420
Claim or source metadata contains an explicit term marker.
Evidence row 497 / uses term
THC studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. PubMed 31595793
Claim or source metadata contains an explicit term marker.
Evidence row 544 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 745 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preliminary human / very_low confidence.
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. PubMed 37721990
Claim or source metadata contains an explicit term marker.
Evidence Group
Insufficient
6 exact rows / 5 sources
Evidence row 196 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 198 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. PubMed 31802404
Claim or source metadata contains an explicit term marker.
Evidence row 226 / uses term
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. PubMed 39630203
Claim or source metadata contains an explicit term marker.
Evidence row 413 / uses term
CBD studied for Sleep.
insufficient / very_low confidence.
Cannabis dosing and administration for sleep: a systematic review. PubMed 36107800
Claim or source metadata contains an explicit term marker.
Evidence row 478 / uses term
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Practical considerations in medical cannabis administration and dosing. PubMed 29307505
Claim or source metadata contains an explicit term marker.
Evidence row 502 / uses term
THC studied for Sleep.
insufficient / very_low confidence.
Cannabis dosing and administration for sleep: a systematic review. PubMed 36107800
Claim or source metadata contains an explicit term marker.
Evidence Group
Preclinical
3 exact rows / 1 source
Evidence row 10 / uses term
CBN increases Total sleep time.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Claim or source metadata contains an explicit term marker.
Evidence row 11 / uses term
CBN increases NREM sleep.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Claim or source metadata contains an explicit term marker.
Evidence row 12 / uses term
CBN increases REM sleep.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Claim or source metadata contains an explicit term marker.
Evidence Group
Mechanistic or Pharmacological
8 exact rows / 7 sources
Evidence row 47 / uses term
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
mechanistic or pharmacological / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 257 / uses term
CBD modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets. PubMed 40432283
Claim or source metadata contains an explicit term marker.
Evidence row 422 / uses term
CBD studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. PubMed 29540584
Claim or source metadata contains an explicit term marker.
Evidence row 562 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. PubMed 35246858
Claim or source metadata contains an explicit term marker.
Evidence row 591 / uses term
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. PubMed 36615835
Claim or source metadata contains an explicit term marker.
Evidence row 751 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Claim or source metadata contains an explicit term marker.
Evidence row 770 / uses term
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats. PubMed 41008636
Claim or source metadata contains an explicit term marker.
Evidence row 791 / uses term
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Claim or source metadata contains an explicit term marker.
Source-Backed Connections
Related pages in the current encyclopedia
No source-backed public page is linked to this term in the current launch set yet. Start with the evidence method, then add sources as the term page matures.
Nearby Terms